RavenQuest Issues Statement in Response to Health Canada Sales License Suspension at Bonify
07 2월 2019 - 8:00PM
RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) –
(CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) CEO, George
Robinson, also acting President & CEO at Bonify, issues the
following statement in response to the February 4 Health Canada
(“HC”) Notice of Suspension for Sales at Bonify Holdings
Corporation (“Bonify”).
“On February 4, 2019, Bonify received a Notice
of Suspension for Sales from Health Canada. Shortly
thereafter, HC issued a statement to the media which outlined the
grounds for suspension. We are disappointed to see large
discrepancies between the Health Canada media statement and the
detailed notice we received in writing. What was presented to
the public was very different than what we received in the written
Notice of Suspension.
Health Canada hand delivered the Notice of
Suspension at 9:30am, February 4, prior to the two-day inspection
that took place on February 4-5, 2019. Of note is the
following timeline:
- Bonify initiated a recall of
product and began corrective action immediately
- December 11-14, 2018: HC
inspects the Bonify facility
- December 14, 2018: Bonify
begins additional corrective actions based upon HC verbal
debrief
- December 21, 2018: HC reports
written findings to Bonify
- January 9: Bonify responds to
HC’s observations
- January 19: HC requests
additional information with a February 1 due date, later extended
to February 11 at Bonify’s request
- February 4: HC delivers
Notice of Suspension to Bonify prior to the Bonify facility
inspection
Bonify is entitled to respond to the Notice of
Suspension within 10 days and will vigorously defend its license by
providing reasons why the suspension is unfounded.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development. RavenQuest is a licensed producer
with facilities located in Markham, Ontario and Edmonton,
Alberta.
RavenQuest maintains a research partnership with
Montreal’s McGill University focused upon cultivar (strain)
recognition, plant stabilization and yield maximization of the
cannabis plant. The Company focuses on partnerships with
Indigenous communities.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson” Chief Executive Officer
For further information, please contact: Mathieu
McDonald, Corporate Communications – 1-877-282-1568
Neither Canadian Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Stock Exchange) accepts responsibility for
the adequacy or accuracy of this press release, which has been
prepared by management.
Cautionary Note Regarding Forward-Looking
Statements
All statements in this press release, other than
statements of historical fact, are “forward-looking information”
with respect to the Company within the meaning of applicable
securities laws, including statements with respect to the
development of licensed cannabis production facilities, the
production and supply of cannabis to the BCLDB, .the launch of
consumer cannabis brands and the development of partnerships with
Indigenous communities. The Company provides forward-looking
statements for the purpose of conveying information about current
expectations and plans relating to the future and readers are
cautioned that such statements may not be appropriate for other
purposes. By its nature, this information is subject to inherent
risks and uncertainties that may be general or specific and which
give rise to the possibility that expectations, forecasts,
predictions, projections or conclusions will not prove to be
accurate, that assumptions may not be correct and that objectives,
strategic goals and priorities will not be achieved. These risks
and uncertainties include but are not limited to those identified
and reported in the Company’s public filings under the Company’s
SEDAR profile at www.sedar.com. Although the Company has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking information, there may be other
factors that cause actions, events or results not to be as
anticipated, estimated or intended. There can be no assurance that
such information will prove to be accurate as actual results and
future events could differ materially from those anticipated in
such statements. The Company disclaims any intention or
obligation to update or revise any forward-looking information,
whether as a result of new information, future events or otherwise
unless required by law.
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
RavenQuest BioMed (CSE:RQB)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024